ID,Drug,Disease,Edge_Inference_type Rx00042,bevacizumab,metastatic colorectal cacner,Primary indication Rx00042,bevacizumab,metastatic carcinoma of the colon,Primary indication Rx00042,bevacizumab,metastatic carcinoma of the rectum,Primary indication Rx00042,bevacizumab,non-squamous non-small cell lung cancer,Primary indication Rx00042,bevacizumab,adult glioblastoma,Primary indication Rx00042,bevacizumab,unresectable non-squamous non-small cell lung cancer,Primary indication Rx00042,bevacizumab,locally advanced non-squamous non-small cell lung cancer,Primary indication Rx00042,bevacizumab,recurrent non-squamous non-small cell lung cancer,Primary indication Rx00042,bevacizumab,metastatic non-squamous non-small cell lung cancer,Primary indication Rx00042,bevacizumab,ovarian cancer,Secondary indication Rx00042,bevacizumab,pancreatic cancer,Secondary indication Rx00042,bevacizumab,stomach cancer,Secondary indication Rx00042,bevacizumab,melanoma,Secondary indication Rx00042,bevacizumab,Glioblastoma,Secondary indication Rx00042,bevacizumab,metastatic colorectal cancer,Secondary indication Rx00042,bevacizumab,non-squamous non-small cell lung cancer,Secondary indication Rx00042,bevacizumab,metastatic breast cancer,Secondary indication Rx00042,bevacizumab,metastatic renal cell carcinoma,Secondary indication